|
| 应用不同栓塞剂的肝动脉化疗栓塞术治疗原发性肝癌的效果评价 |
| Effect evaluation of transcatheter arterial chemoembolization with different embolic agents in treatment of primary liver cancer |
| 投稿时间：2020-04-11 |
| DOI：10.3969/j.issn.1000-0399.2020.10.005 |
| 中文关键词: 原发性肝癌 肝动脉化疗栓塞术 CalliSpheres载药微球 碘化油 |
| 英文关键词: Primary liver cancer Transcatheter arterial chemoembolization Callispheresdrug-loaded microspheres Iodized oil |
| 基金项目:安徽省重点研究与开发计划项目（项目编号：1804h08020227） |
|
| 摘要点击次数: 1128 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 评价载药微球-肝动脉化疗栓塞术（DEB-TACE）与传统肝动脉化疗栓塞术（cTACE）治疗原发性肝癌的效果。方法 回顾性分析2017年1月至2019年12月安徽医科大学第一附属医院介入科100例接受TACE治疗患者的临床资料，根据术中应用不同的栓塞剂分为DEB-TACE组（48例）和cTACE组（52例）。比较两组术后1个月疾病缓解率和控制率，分析手术前后两组血清甲胎蛋白（AFP）、肝功能指标的变化及术后并发症情况。结果 DEB-TACE组肿瘤控制率达95.83%，明显优于cTACE组（80.77%），差异有统计学意义（P<0.05）。DEB-TACE组患者总胆红素（TBIL）、谷草转氨酶（AST）以及谷丙转氨酶（ALT）较术前均升高，且升高幅度低于cTACE组，差异均有统计学意义（P<0.05）；DEB-TACE组患者的AFP水平较术前大幅下降，且下降幅度高于cTACE组，差异有统计学意义（P<0.05）。两组患者发热、腹痛、呕吐等并发症比较，差异无统计学意义（P>0.05）。结论 DEB-TACE治疗原发性肝癌可保护患者肝功能，且其近期临床疗效以及安全性明显优于cTACE，值得临床推广。 |
| 英文摘要: |
| Objective To evaluate the effect of drug-eluting beads transcatheter arterial chemoembolization (DEB-TACE) and conventional transarterial chemoembolization (cTACE) in the treatment of primary liver cancer. Methods A retrospective analysis of the clinical data of 100 patients receiving TACE treatment in the Interventional Department of the First Affiliated Hospital of Anhui Medical University from Jan 2017 to Dec 2019 were divided into DEB-TACE group (48 cases) and cTACE group (52 cases) according to the intraoperative application of different embolic agents. The disease remission rate and control rate of one month after operation, the changes of serum AFP level, liver function indexes and postoperative complications were compared between the two groups. Results The tumor control rate of DEB-TACE group reached 95.83%, which was significantly better than that of cTACE group (80.77%), and the difference was statistically significant (P<0.05). The TBIL, AST, and ALT of the DEB-TACE group were higher than those before the operation, the increase was lower than that of cTACE group, and the difference was statistically significant (P<0.05).The AFP level of patients in DEB-TACE group was significantly lower than that before the operation, the decline was higher than that of cTACE group, and the difference was statistically significant (P<0.05).There was no significant difference between the two groups of patients in complications such as fever, abdominal pain, and vomiting (P>0.05). Conclusion DEB-TACE treatment of primary liver cancer can protect the liver function of patients, and its short-term clinical efficacy and safety are significantly better than those of cTACE, which is worth clinical promotion. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
